Indeed, different panPI3K inhibitors (LY294002, BKM120) or the dual PI3K/mTORC1/2 inhibitor BEZ235 alone and in combination with mTORC1 inhibitors and a MEK inhibitor, respectively, have shown anti-tumor potential in NET cells in vitro and in vivo [17, 18, 27–31]. This evidence concerns the gene MAP2K7 and neoplasm.